Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children (FSGS pediatric)
Treatment of Drug-resistant Pediatric Primary Focal Segmental Glomerulosclerosis Using the Liposorber® LA-15 System
Sponsor: Kaneka Medical America LLC
Listed as NCT02235857, this NA trial focuses on Focal Segmental Glomerulosclerosis and remains actively recruiting participants. Sponsored by Kaneka Medical America LLC, it has been updated 13 times since 2015, reflecting substantial change activity. Mental health research at this phase helps define safety and dosing parameters for future study.
Status Flow
Change History
13 versions recorded-
May 2025 — Present [monthly]
Recruiting NA
-
Apr 2025 — May 2025 [monthly]
Recruiting NA
-
Nov 2024 — Apr 2025 [monthly]
Recruiting NA
-
Sep 2024 — Nov 2024 [monthly]
Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Recruiting NA
▶ Show 8 earlier versions
-
Apr 2023 — Jul 2024 [monthly]
Recruiting NA
-
May 2022 — Apr 2023 [monthly]
Recruiting NA
-
May 2021 — May 2022 [monthly]
Recruiting NA
-
Jan 2021 — May 2021 [monthly]
Recruiting NA
-
Apr 2020 — Jan 2021 [monthly]
Recruiting NA
-
Oct 2018 — Apr 2020 [monthly]
Recruiting NA
-
Jun 2018 — Oct 2018 [monthly]
Recruiting NA
-
Jan 2017 — Jun 2018 [monthly]
Recruiting NA
First recorded
May 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Kaneka Medical America LLC
For direct contact, visit the study record on ClinicalTrials.gov .